Watchlist Price Alert

CureVac N.V. (CVAC)

NASDAQ: CVAC · Real-Time Price · USD

5.44

0.06 (1.12%)

At close: Jun 30, 2025, 3:59 PM

5.36

-1.47%

After-hours: Jun 30, 2025, 05:13 PM EDT

1.12% (1D)

Bid	5.25
Market Cap	1.22B
Revenue (ttm)	523.7M
Net Income (ttm)	180.66M
EPS (ttm)	0.92
PE Ratio (ttm)	5.91
Forward PE	-10.8
Analyst	Hold

Ask	5.45
Volume	932,914
Avg. Volume (20D)	1,162,869
Open	5.38
Previous Close	5.38
Day's Range	5.38 - 5.45
52-Week Range	2.37 - 5.72
Beta	2.49

About CVAC

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol CVAC

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for CVAC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Next Earnings Release

CureVac N.V. is scheduled to release its earnings on Aug 14, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

2 weeks ago

+37.59%

CureVac shares are trading higher after BioNTech a... Unlock content with Pro Subscription

1 month ago

+10.59%

CureVac shares are trading higher following Q1 reported financial results.

News

1 week ago · accessnewswire.com

CureVac Announces Voting Results of General Meeting

TÜBINGEN, GERMANY AND BOSTON, MA / ACCESS Newswire / June 24, 2025 / CureVac N.V. (NASDAQ:CVAC), a pioneering multinational biotech company developing a new class of transformative medicines based on ...

1 week ago · zacks.com

CureVac Soars 41% in a Month on a $1.25B Buyout Offer From BioNTech

CVAC jumps 41% in a month after signing a $1.25B deal to be acquired by BioNTech to accelerate mRNA therapy development.

2 weeks ago · investopedia.com

Top Stock Movers Now: Oracle, Boeing, CureVac, and More

U.S. equities were mixed and little changed at midday as another key measure of inflation, the Producer Price Index (PPI), came in lower than expected. The S&P 500 and Nasdaq advanced, while the Dow J...

2 weeks ago · schaeffersresearch.com

CureVac Stock Soars on BioNTech Buyout

Biotech stock CureVac NV (NASDAQ:CVAC) was last seen up 32.2% at $5.37, after news that BioNTech (BNTX) is acquiring the company in all-stock deal worth $1.25 billion.

2 weeks ago · benzinga.com

BioNTech Expands mRNA Cancer Portfolio With CureVac $1.25 Billion All-Stock Deal

BioNTech SE BNTX on Thursday agreed to acquire CureVac N.V. CVAC in an all-stock transaction.

2 weeks ago · proactiveinvestors.com

BioNTech boosts cancer mRNA pipeline with CureVac acquisition

BioNTech (NASDAQ:BNTX) announced that it is acquiring CureVac (NASDAQ:CVAC), a fellow German mRNA vaccine developer, in an all-stock deal valued at approximately $1.25 billion. Under the deal terms, e...

2 weeks ago · businesswire.com

CVAC Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of CureVac N.V. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of CureVac N.V. (NASDAQ: CVAC) to BioNTech SE is fair to CureVac shareholders. Under the ter...

2 weeks ago · barrons.com

BioNTech to Buy CureVac in $1.25 Billion Deal. Both Stocks Are Rising.

CureVac stock soared 29% $5.26 in premarket trading immediately following the news.

2 weeks ago · reuters.com

BioNTech to acquire CureVac in $1.25 billion all-stock deal

German biotech firm BioNTech said on Thursday it agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares to boost its work on new mRNA-based cancer treatments.

1 month ago · accessnewswire.com

CureVac Announces Financial Results for the First Quarter of 2025 and Provides Business Updates

U.S. FDA clears lung cancer IND for CVHNLC, a proprietary off-the-shelf candidate targeting squamous non-small cell lung cancer (sqNCLC), with clinical study expected to begin H2 2025; Clinical Trial ...

Load More News